{"groups":[{"description":"Induction Cycles 1-3: Methotrexate 8gm/m\\^2 days 1 \\& 15; Leucovorin 100 mg/m\\^2 days 2 \\& 16; Rituximab 375 mg/m\\^2 days 3, 10, 17 \\& 24 of cycle 1, days 3 \\& 10 of cycle 2; Temozolomide 150 mg/m\\^2/day PO days 7-11\n\nInduction Cycle 4: Temozolomide 150 mg/m\\^2/day PO days 7-11; Methotrexate 8gm/m\\^2 day 15; Leucovorin 100 mg/m\\^2 day 16\n\nConsolidation Cycle 5: Methotrexate 8gm/m\\^2 days 1; Leucovorin 100 mg/m\\^2 days 2; Temozolomide 150 mg/m\\^2/day PO days 7-11\n\nConsolidation Cycle 6: Cytarabine 2 g/m\\^2 (x 8 doses) days 1-4; Etoposide 5 mg/kg (x 8 doses) days 1-4; G-CSF 5 mcg/kg/day or GM-CSF 250 mcg/m\\^2/day starting day 14 until ANC recovers (\\>= 500 for 2 consecutive days or \\>= 1500 for one day)","id":"FG000","title":"Intensive Combination Chemo & Immunotherapy"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"9"}],"type":"Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Failed (to respond) during induction"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Physician Decision"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"44"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"26"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"18"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Three participants were excluded from analysis because of failure to meet eligibility criteria or to receive protocol therapy.","recruitmentDetails":"Between October 2004 and November 2009, 47 participants were recruited at 12 CALGB sites."}